Piper Sandler Reiterates Overweight Rating on Moderna (MRNA), PT $214
Tweet Send to a Friend
Piper Sandler analyst Edward A. Tenthoff reiterated an Overweight rating and $214.00 price target on Moderna (NASDAQ: MRNA)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
